146 related articles for article (PubMed ID: 36444741)
1. Baseline ALBI score and early variation of serum AFP predicts outcomes in patients with HCC treated by atezolizumab-bevacizumab.
Campani C; Bamba-Funck J; Campion B; Sidali S; Blaise L; Ganne-Carrié N; Demory A; Sutter O; Larrey E; Evain M; Ghannouchi H; Wagner M; Marra F; Sutton A; Allaire M; Nault JC
Liver Int; 2023 Mar; 43(3):708-717. PubMed ID: 36444741
[TBL] [Abstract][Full Text] [Related]
2. Reproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice: Results of the AB-real study.
Fulgenzi CAM; Cheon J; D'Alessio A; Nishida N; Ang C; Marron TU; Wu L; Saeed A; Wietharn B; Cammarota A; Pressiani T; Personeni N; Pinter M; Scheiner B; Balcar L; Napolitano A; Huang YH; Phen S; Naqash AR; Vivaldi C; Salani F; Masi G; Bettinger D; Vogel A; Schönlein M; von Felden J; Schulze K; Wege H; Galle PR; Kudo M; Rimassa L; Singal AG; Sharma R; Cortellini A; Gaillard VE; Chon HJ; Pinato DJ
Eur J Cancer; 2022 Nov; 175():204-213. PubMed ID: 36148739
[TBL] [Abstract][Full Text] [Related]
3. Tumor burden score-AFP-albumin-bilirubin grade score predicts the survival of patients with hepatocellular carcinoma after liver resection.
Qiu ZC; Li C; Zhang Y; Xie F; Yu Y; Leng SS; Chen TH; Wen TF
Langenbecks Arch Surg; 2023 Jun; 408(1):250. PubMed ID: 37382724
[TBL] [Abstract][Full Text] [Related]
4. Current Role of Atezolizumab Plus Bevacizumab Therapy in the Sequential Treatment of Unresectable Hepatocellular Carcinoma.
Komatsu S; Yano Y; Fujishima Y; Ishida J; Kido M; Kuramitsu K; Yamamoto A; Goto T; Yanagimoto H; Toyama H; Ueda Y; Kodama Y; Fukumoto T
Anticancer Res; 2022 Mar; 42(3):1403-1412. PubMed ID: 35220233
[TBL] [Abstract][Full Text] [Related]
5. Reclassification of therapeutic response of unresectable hepatocellular carcinoma to anti-angiogenic therapy and immunotherapy using alpha RECIST.
Xu Y; Yang Y; Ouyang J; Zhou Y; Li L; Ye F; Yang H; Huang Z; Zhou A; Zhang W; Zhou J; Zhao X; Zhao H
Eur Radiol; 2024 Apr; 34(4):2244-2255. PubMed ID: 37740779
[TBL] [Abstract][Full Text] [Related]
6. Validation and prognostic value of EZ-ALBI score in patients with intermediate-stage hepatocellular carcinoma treated with trans-arterial chemoembolization.
Ananchuensook P; Sriphoosanaphan S; Suksawatamnauy S; Siripon N; Pinjaroen N; Geratikornsupuk N; Kerr SJ; Thanapirom K; Komolmit P
BMC Gastroenterol; 2022 Jun; 22(1):295. PubMed ID: 35701739
[TBL] [Abstract][Full Text] [Related]
7. A new ALBI-based model to predict survival after transarterial chemoembolization for BCLC stage B hepatocellular carcinoma.
Lee IC; Hung YW; Liu CA; Lee RC; Su CW; Huo TI; Li CP; Chao Y; Lin HC; Hou MC; Huang YH
Liver Int; 2019 Sep; 39(9):1704-1712. PubMed ID: 31319016
[TBL] [Abstract][Full Text] [Related]
8. Combination of alpha-fetoprotein and neutrophil-to-lymphocyte ratio to predict treatment response and survival outcomes of patients with unresectable hepatocellular carcinoma treated with immune checkpoint inhibitors.
Zhu HF; Feng JK; Xiang YJ; Wang K; Zhou LP; Liu ZH; Cheng YQ; Shi J; Guo WX; Cheng SQ
BMC Cancer; 2023 Jun; 23(1):547. PubMed ID: 37322411
[TBL] [Abstract][Full Text] [Related]
9. Albumin-Bilirubin Grade Analyses of Atezolizumab plus Bevacizumab versus Sorafenib in Patients with Unresectable Hepatocellular Carcinoma: A Post Hoc Analysis of the Phase III IMbrave150 Study.
Kudo M; Finn RS; Cheng AL; Zhu AX; Ducreux M; Galle PR; Sakamoto N; Kato N; Nakano M; Jia J; Vogel A
Liver Cancer; 2023 Oct; 12(5):479-493. PubMed ID: 37901766
[TBL] [Abstract][Full Text] [Related]
10. Early Changes in Alpha-Fetoprotein Are a Useful Predictor of Efficacy of Atezolizumab plus Bevacizumab Treatment in Patients with Advanced Hepatocellular Carcinoma.
Kuzuya T; Kawabe N; Hashimoto S; Miyahara R; Sawaki A; Nakano T; Nakaoka K; Tanaka H; Miyachi Y; Mii A; Kamejima S; Takahara T; Kato Y; Sugioka A; Hirooka Y
Oncology; 2022; 100(1):12-21. PubMed ID: 34731863
[TBL] [Abstract][Full Text] [Related]
11. Combination of neutrophil/lymphocyte ratio and albumin/bilirubin grade as a prognostic predictor for hepatocellular carcinoma patients undergoing curative hepatectomy.
Luo H; Huang C; Meng M; Zhang M; Li Z; Huang J
BMC Gastroenterol; 2023 May; 23(1):162. PubMed ID: 37208618
[TBL] [Abstract][Full Text] [Related]
12. A novel prognostic model based on AFP, tumor burden score and Albumin-Bilirubin grade for patients with hepatocellular carcinoma undergoing radiofrequency ablation.
Huang J; Cui W; Xie X; Lin K; Jin D; Xie X; Zhuang B
Int J Hyperthermia; 2023; 40(1):2256498. PubMed ID: 37733400
[TBL] [Abstract][Full Text] [Related]
13. Combination of CRAFITY score with Alpha-fetoprotein response predicts a favorable outcome of atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma.
Teng W; Lin CC; Su CW; Lin PT; Hsieh YC; Chen WT; Ho MM; Wang CT; Chai PM; Hsieh JC; Lin CY; Lin SM
Am J Cancer Res; 2022; 12(4):1899-1911. PubMed ID: 35530282
[TBL] [Abstract][Full Text] [Related]
14. Alpha-Fetoprotein as a Potential Surrogate Biomarker for Atezolizumab + Bevacizumab Treatment of Hepatocellular Carcinoma.
Zhu AX; Dayyani F; Yen CJ; Ren Z; Bai Y; Meng Z; Pan H; Dillon P; Mhatre SK; Gaillard VE; Hernandez S; Kelley RK; Sangro B
Clin Cancer Res; 2022 Aug; 28(16):3537-3545. PubMed ID: 35435967
[TBL] [Abstract][Full Text] [Related]
15. A New Prognostic Model Based on Albumin-Bilirubin Grade for Hepatocellular Carcinoma Beyond the Milan Criteria.
Ho SY; Liu PH; Hsu CY; Hsia CY; Huang YH; Su CW; Lei HJ; Lee RC; Hou MC; Huo TI
Dig Dis Sci; 2020 Feb; 65(2):658-667. PubMed ID: 31659612
[TBL] [Abstract][Full Text] [Related]
16. No correlation between MASLD and poor outcome of Atezolizumab-Bevacizumab therapy in patients with advanced HCC.
Copil FD; Campani C; Lequoy M; Sultanik P; Blaise L; Wagner M; Ganne-Carrié N; Ozenne V; Thabut D; Nault JC; Ratziu V; Allaire M
Liver Int; 2024 Apr; 44(4):931-943. PubMed ID: 38291735
[TBL] [Abstract][Full Text] [Related]
17. Early alpha-foetoprotein response associated with treatment efficacy of immune checkpoint inhibitors for advanced hepatocellular carcinoma.
Shao YY; Liu TH; Hsu C; Lu LC; Shen YC; Lin ZZ; Cheng AL; Hsu CH
Liver Int; 2019 Nov; 39(11):2184-2189. PubMed ID: 31400295
[TBL] [Abstract][Full Text] [Related]
18. Optimal threshold of alpha-fetoprotein response in patients with unresectable hepatocellular carcinoma treated with atezolizumab and bevacizumab.
Tamaki N; Tada T; Kurosaki M; Yasui Y; Ochi H; Mashiba T; Sakamoto A; Marusawa H; Narita R; Uchida Y; Akahane T; Kondo M; Mori N; Takaki S; Tsuji K; Kobashi H; Kusakabe A; Furuta K; Arai H; Nonogi M; Ogawa C; Sato T; Tamada T; Nakamura S; Hasebe C; Tsuchiya K; Izumi N
Invest New Drugs; 2022 Dec; 40(6):1290-1297. PubMed ID: 36152108
[TBL] [Abstract][Full Text] [Related]
19. Development and validation of a modified albumin-bilirubin grade and α-fetoprotein score (mALF score) for hepatocellular carcinoma patients receiving atezolizumab and bevacizumab.
Hatanaka T; Kakizaki S; Hiraoka A; Tada T; Hirooka M; Kariyama K; Tani J; Atsukawa M; Takaguchi K; Itobayashi E; Fukunishi S; Tsuji K; Ishikawa T; Tajiri K; Ochi H; Yasuda S; Toyoda H; Ogawa C; Nishimura T; Shimada N; Kawata K; Kosaka H; Tanaka T; Ohama H; Nouso K; Morishita A; Tsutsui A; Nagano T; Itokawa N; Okubo T; Arai T; Imai M; Naganuma A; Koizumi Y; Nakamura S; Kaibori M; Iijima H; Hiasa Y; Kumada T;
Hepatol Int; 2023 Feb; 17(1):86-96. PubMed ID: 36076009
[TBL] [Abstract][Full Text] [Related]
20. The ALBI Grade is a Good Predictive Model for Very Late Recurrence in Patients with Hepatocellular Carcinoma Undergoing Primary Resection.
Lin CY; Lin CC; Wang CC; Chen CL; Hu TH; Hung CH; Huang PY; Tsai MC
World J Surg; 2020 Jan; 44(1):247-257. PubMed ID: 31559485
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
